Atos Group – Availability of the 2025 Half-year Financial Report
Availability of the 2025 Half-year Financial Report
Paris, August 1, 2025 – Atos Group announces that its 2025 half-year financial report was published today on its website and filed with the French Financial Markets Authority ('AMF').
This document includes the 2025 half-year activity report, the financial statements for the first of 2025, the statutory auditors' review report and the statement of the responsible person for the half-year financial report.
It is available, in English and in French, on the Company's website (www.atos.net).
About Atos Group
Atos Group is a global leader in digital transformation with c. 70,000 employees and annual revenue of c. € 10 billion, operating in 67 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos is a SE (Societas Europaea) and listed on Euronext Paris.
The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.
Contact
Investor relations: [email protected]
Individual shareholders: +33 8 05 65 00 75
Attachment PR – Atos Group – 20250801 – 2025 Half-year Financial Report
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
22 minutes ago
- Entrepreneur
Earth Observation: A New Frontier of Resilience for European Entrepreneurs
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Europe, an international franchise of Entrepreneur Media. Our fast-changing climate is hitting businesses hard. Every three weeks, a billion-dollar extreme weather event hits, wreaking havoc on global supply chains and denting business for large and small companies alike. It's a risk that European business owners can't continue to ignore as Europe is the fastest-warming continent. The devastating floods that hit Spain late last year also put a huge strain on its economy, costing the Spanish more than 10 billion euros. Over a year's worth of rain hit in eight hours, creating a nightmare situation for businesses and residents alike, whose properties were destroyed. Entrepreneurs need to take a proactive approach to managing challenges like these. There's a clear business case for being prepared before disaster strikes: According to the U.S. Chamber of Commerce, every $1 invested in climate resilience saves businesses $13. That's where Earth Observation (EO) data comes in. EO is the science of using sensors found in satellites and other devices to unveil vital information about our planet's surface, such as climate change patterns, land conditions, marine life, security, and more. Governments around the world have been heavily investing in EO given its potential to solve a wide range of problems that plague us here on Earth. The EU's Copernicus is a globally leading EO programme, set to generate up to €131 billion for the European economy. The European Space Agency (ESA) has also made headway in its 'Space for Earth' initiative. Just last month, it launched its groundbreaking satellite, Biomass, to uncover new data on how much carbon is stored in our forests and to 3D map them for the first time. Using Earth Observation data to stay ahead of the curve Yet it's not just governments and big organizations that stand to benefit from the capabilities of EO. Entrepreneurs and smaller businesses can also leverage it to answer real-world challenges, like risks to operations and assets. In fact, platforms like Copernicus aren't off-limits for smaller businesses: It's freely accessible for commercial use, combining information from satellite and in-situ (non-space) sources alike. These tools are made of high-quality imaging technology that analyse topography and weather patterns in unparalleled detail, capturing resolutions of 0.3m². What does this mean for entrepreneurs who access these data sources? They can tap into insights to take pre-emptive action for risk management, such as forecasting an otherwise unexpected flash of heavy rain which could cause flooding and destroy warehouses in that area. "It's interesting to see the ways that AI is helping to support the development of Europe's space industry and how it plays a key role in underpinning the convenience and security of our lives on Earth," says Daniel Smith, founder of AstroAgency, a consultancy for the space sector. "Earth Observation data, which comes from sensors on satellites, provides insights to support our economies through business sectors like energy, finance, agriculture, maritime, forestry, and more, as well as broader environmental monitoring efforts." Let's take a look at that in action. An entrepreneur with a small wine company, for instance, can tap into crop yield data at scale via EO data, allowing them to better forecast how much fertilizer and water they will need ahead of the planting season. The European wine industry, as well as the agriculture sectors, is being hit by continent-wide droughts; the use case of EO technology in these industries could be highly useful for business owners shuffling budgets, planning logistics, and trying to predict harvest yield. A founder operating in construction can benefit from EO data, too. A small business owner specialising in recycled concrete for buildings relies on rail to transport materials between regions or even countries. However, a key challenge is keeping a pulse on transport progress and being notified immediately if there are any delays or disruptions so they can act accordingly. Here's where EO insights can improve business operations with satellite-powered radar technology to get instant updates on rail freight. Tapping into those insights also benefits SMEs from a financial standpoint. It's no secret that European banks have some of the most stringent standards for risk management, including climate impact, when issuing funds and loans. Business owners need to prove that they're aligning activities with sustainability goals, but often struggle to uncover the insights needed to guide their steps in doing just that. According to a report from Morgan Stanley, 77% of investors are interested in sustainable investing. That's where companies like D-CAT come in, providing monitoring, reporting, and verification (MRV) services via satellites and machine learning (ML)-powered platforms. They're helping businesses understand where they can make more sustainable choices and show investors how they're slashing risks like climate impact. Be strategic with EO data use While EO data is not an absolute necessity for all entrepreneurs—especially those just starting out—the insights it yields can give a significant competitive advantage. With that in mind, entrepreneurs should be intentional in terms of investing in and prioritising the use of such information. That means having a blueprint in place to guide how these tools are implemented' here's how to do that. First, map out business goals and weaknesses in existing processes. This will enable entrepreneurs to gauge which challenges and opportunities EO data and relevant tools will answer. Next, it's critical to get digital infrastructures ready. Too often, businesses are quick to adopt technologies like AI tools without addressing existing gaps in their digital ecosystem, whether that's poor data management or poor interoperability between existing applications. There's nothing more frustrating than investing time, money, and energy into implementing a new technology, only for it to cause more friction than benefits. Assessing these aspects will also mean business owners can narrow down the EO data tools and solutions most relevant to their business needs—ensuring they bring tangible impact, whether that's fortifying resource availability, safeguarding facilities that are otherwise at risk of extreme weather events, or strengthening risk reporting for investors' assessments. An economic opportunity orbiting overhead EO data could pave the way for a $3.8 trillion economic opportunity, transforming how businesses propel growth while empowering their ESG efforts for stronger risk management. What once was a field viewed as exclusively for astronauts and astronomers is now a frontline for tackling key challenges like climate change head-on. Entrepreneurs who tap into this latest frontier aren't just going to be resilient to risk, but ahead of it, too.
Associated Press
29 minutes ago
- Associated Press
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce significant progress in its global patent portfolio. The Company has received formal communications from both the European Patent Office (EPO) and the Eurasian Patent Organization (EAPO), confirming that the core claims of its patent application covering its proprietary sublingual Cladribine thin-film formulation have been accepted, with full grants anticipated in the near future. The patent further covers all applications of chemotherapy drugs in an oral dissolvable delivery system for the treatment of autoimmune neurological diseases. Advancing Toward Formal Patent Grant European Patent Office (EPO): The EPO has issued an Office Action with the intention to grant for BioNxt's key patent application. This confirmation signifies that all core claims have met the European requirements for novelty, inventive step, and industrial applicability. Only minor formal amendments were requested, which the Company has already addressed. The next Office Action is expected within the coming weeks. Eurasian Patent Organization (EAPO): The EAPO, covering eight member countries across Eastern Europe and Central Asia, has issued a formal notice that BioNxt's patent application has likewise been accepted. Minor language modifications were required and have been promptly submitted. The Company anticipates a full patent grant across all member states in the near term. Global Patent Strategy and Expansion BioNxt previously filed an international patent application under the Patent Cooperation Treaty (PCT) to establish a coordinated framework for securing patent protection for its sublingual Cladribine thin-film technology and future products in multiple key markets. The Company has entered the national phase of this application in major pharmaceutical jurisdictions, including the United States, Canada, Japan, Australia, and New Zealand. These national phase applications are currently progressing through local examination procedures. Patent protection in these regions will support BioNxt's long-term strategy for global commercialization, regulatory alignment, and regional partnership development. Protecting Innovation in Multiple Sclerosis (MS) Treatment The patents under review are designed to protect a family of products, including BioNxt's Cladribine-based thin-film formulation, developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). The platform uses sublingual administration to optimize drug absorption, improve patient compliance, and avoid first-pass hepatic metabolism, offering a patient-friendly alternative to injectable or conventional oral therapies. Patent protections include composition of the sublingual film, methods of administration and dosage, use for treating autoimmune diseases, and scalable manufacturing processes. 'Securing intellectual property rights in both Europe and Eurasia marks a critical step forward for our Cladribine program and sublingual delivery platform,' said Hugh Rogers, CEO of BioNxt Solutions. 'These patents represent significant commercial value by protecting a high-potential product, enabling regional exclusivity, and enhancing our ability to generate future licensing and partnership revenue.' Next Milestones in Patent Issuance and Product Advancement BioNxt expects formal grant notices and publication from both the EPO and EAPO shortly. In parallel, the Company is preparing for GMP manufacturing and a human bioequivalence clinical study in Europe to support regulatory filings and commercialization. Further updates will be provided as additional national patent offices complete their evaluations. About BioNxt Solutions Inc. BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit Investor Relations & Media Contact Hugh Rogers, Co-Founder, CEO and Director Email: [email protected] Phone: +1 780-818-6422 Web: LinkedIn: Instagram: Cautionary Statement Regarding 'Forward-Looking' Information This press release contains 'forward-looking information' and 'forward-looking statements' within the meaning of applicable Canadian securities laws (collectively, 'forward-looking information'). Forward-looking information includes, but is not limited to, statements regarding the anticipated grant and scope of European and Eurasian patent rights; the Company's plans for additional international patent filings; the development, clinical evaluation, and commercialization of the Company's Cladribine thin-film (BNT23001) for multiple sclerosis; the strategic importance of intellectual property; the timing and outcome of regulatory processes; and the potential expansion of BioNxt's sublingual drug delivery platform to other therapeutic areas. Forward-looking information is based on management's reasonable assumptions, expectations, estimates, and projections as of the date of this press release. These statements are subject to known and unknown risks, uncertainties, and other factors-many of which are beyond the Company's control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: patent examination and prosecution outcomes; changes in regulatory or legal frameworks; clinical trial results; scalability of manufacturing processes; strategic partnership risks; and broader economic, financial, or geopolitical conditions. Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes that the expectations and assumptions reflected in such statements are reasonable, there can be no assurance that they will prove to be correct. Except as required by applicable securities laws, BioNxt undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. SOURCE: BioNxt Solutions Inc. press release
Business Wire
an hour ago
- Business Wire
Important Notice of Dividend Announcement to shareholder of Xtrackers (IE) plc
LONDON--(BUSINESS WIRE)-- Registered in Dublin, Ireland as an open-ended variable capital umbrella investment company with limited liability and as an umbrella fund with segregated liability between sub-funds. Registration Number 393802. Registered Office as above. Directors: Tom Murray (Irish), Michael Whelan (Irish), Gerry Grimes (Irish), Philippe Ah-Sun (British), Julien Boulliat (French) and Roberto Cesca (Italian). Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the ' Company ') Important Notice to Shareholders of the Company Dividend Announcement 5 August 2025 Dividend announcement with regard to the following Funds of the Company The Board of Directors wishes to inform Shareholders that a dividend per share for certain Classes of Shares and Funds will be paid, as set out below. Please note the following dates which apply to all of the below: Ex-dividend date: 20 August 2025 Record date: 21 August 2025 Payment date: 4 September 2025 Fund Xtrackers MSCI World Screened UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1116 ISIN Code IE00BCHWNQ94 Expand Fund Xtrackers MSCI USA Energy UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.6232 ISIN Code IE00BCHWNS19 Expand Fund Xtrackers MSCI USA Financials UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2258 ISIN Code IE00BCHWNT26 Expand Fund Xtrackers MSCI USA Health Care UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3933 ISIN Code IE00BCHWNW54 Expand Fund Xtrackers MSCI USA Minimum Volatility UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3714 ISIN Code IE00BDB7J586 Expand Fund Xtrackers USD High Yield Corporate Bond UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1958 ISIN Code IE00BDR5HM97 Expand Fund Xtrackers MSCI USA Banks UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3137 ISIN Code IE00BDVPTJ63 Expand Fund Xtrackers ESG USD Emerging Markets Bond Quality Weighted UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2418 ISIN Code IE00BD4DX952 Expand Fund Xtrackers USD Corporate Bond Short Duration SRI PAB UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3386 ISIN Code IE00BF8J5974 Expand Fund Xtrackers MSCI USA Consumer Staples UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4785 ISIN Code IE00BGQYRQ28 Expand Fund Xtrackers MSCI USA Consumer Discretionary UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2194 ISIN Code IE00BGQYRR35 Expand Fund Xtrackers MSCI USA Information Technology UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2305 ISIN Code IE00BGQYRS42 Expand Fund Xtrackers S&P Europe ex UK UCITS ETF Share Class 1D Denomination Currency EUR Amount/Share (gross) 1.2498 ISIN Code IE00BGV5VM45 Expand Fund Xtrackers MSCI World UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4923 ISIN Code IE00BK1PV551 Expand Fund Xtrackers MSCI Japan Screened UCITS ETF Share Class 1D Denomination Currency JPY Amount/Share (gross) 25.5250 ISIN Code IE00BPVLQD13 Expand Fund Xtrackers MSCI Japan Screened UCITS ETF Share Class 2D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.2477 ISIN Code IE00BPVLQF37 Expand Fund Xtrackers USD Corporate Bond UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1484 ISIN Code IE00BZ036H21 Expand Fund Xtrackers MSCI World UCITS ETF Share Class 2D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1071 ISIN Code IE00BZ1BS790 Expand Fund Xtrackers MSCI Nordic UCITS ETF Share Class 1D Denomination Currency EUR Amount/Share (gross) 1.1481 ISIN Code IE00B9MRHC27 Expand Fund Xtrackers MSCI USA Industrials UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4638 ISIN Code IE00BCHWNV48 Expand Fund Xtrackers MSCI USA Communication Services UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3070 ISIN Code IE00BNC1G707 Expand Fund Xtrackers MSCI Emerging Markets UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0726 ISIN Code IE000GWA2J58 Expand Fund Xtrackers S&P 500 Equal Weight UCITS ETF Share Class 1D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.0252 ISIN Code IE000N5GJDD7 Expand Fund Xtrackers USD Corporate Green Bond UCITS ETF Share Class 1D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1696 ISIN Code IE000X63FXN4 Expand Fund Xtrackers MSCI USA ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0222 ISIN Code IE000UMV0L21 Expand Fund Xtrackers USD High Yield Corporate Bond UCITS ETF Share Class 4D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1081 ISIN Code IE00BG04LV15 Expand Fund Xtrackers MSCI USA Climate Transition UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1112 ISIN Code IE000GYDNJS5 Expand Fund Xtrackers MSCI Japan Climate Transition UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0402 ISIN Code IE0006FDYJF8 Expand Fund Xtrackers S&P 500 Equal Weight UCITS ETF Share Class 2D Denomination Currency USD Amount/Share (gross) 0.2938 ISIN Code IE000CXLGK86 Expand Fund Xtrackers USD Corporate Bond UCITS ETF Share Class 5D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.0848 ISIN Code IE00BG04LY46 Expand Fund Xtrackers MSCI USA High Dividend Yield ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1429 ISIN Code IE000V04SL39 Expand Fund Xtrackers MSCI World High Dividend Yield ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3040 ISIN Code IE000NS5HRY9 Expand Fund Xtrackers MSCI World ex USA UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1083 ISIN Code IE000Z0FC0G5 Expand Should you have any queries in this regard please do not hesitate to contact your relationship manager directly. Capitalised terms used in this letter shall have the meaning ascribed to them in the current Prospectus of the Company unless the context otherwise requires. We thank you for your continuing support of the Company. Yours faithfully, _______________ Director For and on behalf of Xtrackers (IE) plc Contact Information Xtrackers (IE) plc 78 Sir John Rogerson's Quay Dublin 2, Ireland
